Please login to the form below

Not currently logged in
Email:
Password:

Sanofi Pasteur and Vivalis collaboration

Sanofi Pasteur has announced its partnership with Vivalis for the discovery and development of antibody treatments

Sanofi Pasteur, the vaccines division of sanofi-aventis (S-A), has announced its partnership with biopharmaceutical company, Vivalis, for the discovery and development of antibody treatments.

The collaboration will see Sanofi Pasteur acquire exclusive access to Vivalis' Humalex platform – a range of technologies for the discovery of fully human monoclonal antibodies targeting clinically significant infectious diseases.

Monoclonal antibodies are used in therapies to bind to specific target cells to stimulate the patient's immune system to attack the cells.

Sanofi Pasteur will also gain worldwide exclusive development and commercialisation rights for the discovered antibodies.

In return, Vivalis will receive an upfront payment of €3m, with potential milestone payments of up to €35m for each infectious disease therapy over the course of the development stage. The company will also receive royalty payments from future product sales.

"We are pleased to team up with Vivalis to discover and develop new biologicals against infectious diseases for patients worldwide," said Michel de Wilde, senior vice president, Research and Development, Sanofi Pasteur.

"Vivalis' Humalex technology allows rapid identification of clinically relevant fully human antibodies, as well as their related antigen. This opens up new medical solutions to prevent or treat serious infections."

Franck Grimaud, CEO of Vivalis, said: "This is the first major commercial agreement on the Humalex platform but it also represents a strong validation of the technology. Vivalis is today one of a very few companies able to propose a fully integrated offering from the discovery of fully human monoclonal antibodies to the production of clinical batches."

8th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics